On June 29, Remegen rose 5.38% in regular trading, trading at HK$72.85/share, with turnover of HK$72.75 million.

On the news front, the company announced that 193 million IPO lock-up shares (34.16% of total equity) will become eligible for trading on July 1. However, due to the company's cash dividends falling short of regulatory requirements under Shanghai Stock Exchange guidelines, the unlocked shareholders are prohibited from reducing holdings via centralized bidding or block trades on A-shares, significantly alleviating actual selling pressure below market expectations.

Additionally, the company's core product Telitacicept (RC18), a first-in-class BLyS/APRIL dual-target fusion protein, recently received NMPA approval for two new indications — Sjogren's syndrome and IgA nephropathy — marking the first approved biologic for Sjogren's syndrome globally. Telitacicept now has five approved indications domestically, strengthening commercialization ramp-up expectations.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)